CA3252552A1 - Brm targeting compounds and associated methods of use - Google Patents

Brm targeting compounds and associated methods of use

Info

Publication number
CA3252552A1
CA3252552A1 CA3252552A CA3252552A CA3252552A1 CA 3252552 A1 CA3252552 A1 CA 3252552A1 CA 3252552 A CA3252552 A CA 3252552A CA 3252552 A CA3252552 A CA 3252552A CA 3252552 A1 CA3252552 A1 CA 3252552A1
Authority
CA
Canada
Prior art keywords
pyrazino
methyl
hexahydro
hydroxyphenyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3252552A
Other languages
English (en)
French (fr)
Inventor
John A. Rose
Corey Howard Basch
Song Mei
Klare Lazor Bersh
Danielle Julie Beam ROTH
Katarina ROHLFING
Xiaowei Wu
Artem Shvartsbart
Andrew Paul Combs
Liang Lu
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of CA3252552A1 publication Critical patent/CA3252552A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA3252552A 2022-05-10 2023-05-09 Brm targeting compounds and associated methods of use Pending CA3252552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340185P 2022-05-10 2022-05-10
US63/340,185 2022-05-10
PCT/US2023/066755 WO2023220577A1 (en) 2022-05-10 2023-05-09 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3252552A1 true CA3252552A1 (en) 2023-11-16

Family

ID=86771366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3252552A Pending CA3252552A1 (en) 2022-05-10 2023-05-09 Brm targeting compounds and associated methods of use

Country Status (10)

Country Link
US (1) US20230365576A1 (enExample)
EP (1) EP4522621A1 (enExample)
JP (1) JP2025521091A (enExample)
KR (1) KR20250011136A (enExample)
CN (1) CN119487036A (enExample)
AU (1) AU2023269778A1 (enExample)
CA (1) CA3252552A1 (enExample)
IL (1) IL316891A (enExample)
MX (1) MX2024013843A (enExample)
WO (1) WO2023220577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026090411A1 (en) 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119504710B (zh) * 2024-11-18 2025-10-17 昆明医科大学 靶向降解PRMT5的PROTACs化合物及其应用
CN121873038A (zh) * 2026-03-16 2026-04-17 南开大学 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Also Published As

Publication number Publication date
KR20250011136A (ko) 2025-01-21
JP2025521091A (ja) 2025-07-08
WO2023220577A1 (en) 2023-11-16
MX2024013843A (es) 2025-02-10
IL316891A (en) 2025-01-01
CN119487036A (zh) 2025-02-18
AU2023269778A1 (en) 2024-12-12
US20230365576A1 (en) 2023-11-16
EP4522621A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12448389B2 (en) BRM targeting compounds and associated methods of use
EP4161935B1 (en) Brm targeting compounds and associated methods of use
EP4522621A1 (en) 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
AU2023342153A1 (en) Brm targeting compounds and associated methods of use
EP4619404A1 (en) Brm targeting compounds and associated methods of use
US20230416240A1 (en) Kat6 targeting compounds
WO2023287787A1 (en) Brm targeting compounds and associated methods of use
WO2025101738A1 (en) Brm targeting compounds and associated methods of use
US20250161289A1 (en) KAT6 Targeting Compounds
WO2025184459A1 (en) Brm and brg1 targeting compounds and associated methods of use
AU2024375747A1 (en) Kat6 targeting compounds
WO2026090411A1 (en) Brm and brg1 targeting compounds and associated methods of use
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA050840B1 (ru) Brm направленные соединения и связанные способы применения

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241108

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250205

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250205

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251103